Recce Pharmaceuticals secures approval for Phase 3 trial of R327G in Indonesia
Recce Pharmaceuticals Limited (ASX: RCE) has achieved a significant milestone in its quest to tackle diabetic foot infections (DFIs), a common complication among diabetes patients. ... Read More
Recce Pharmaceuticals to begin Phase 3 trials in Indonesia for diabetic foot infection treatment
Recce Pharmaceuticals Limited has received ethics approval from Indonesia’s Human Research Ethics Committee to initiate Phase 3 clinical trials of its topical gel, RECCE® 327 ... Read More
Recce Pharmaceuticals secures phase II trial safety approval for breakthrough R327G treatment
Recce Pharmaceuticals Limited recently announced significant progress in its phase II clinical trial for RECCE 327 Topical Gel (R327G), an innovative treatment for acute bacterial ... Read More